Skip to content
Catalyst

PapersPMID:42588182

Untargeted 1H-NMR Metabolomics Identifies Candidate Metabolic Changes Associated with Watercress (Nasturtium officinale R.Br.) Supplementation in Adults with Low-to-Moderate Cardiovascular Risk: A Randomized Placebo-Controlled Trial.

Nutrients2026The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, moderate evidenceno difference foundHDL cholesterol
  2. Finding, moderate evidenceno difference foundTriglycerides
Study, every finding
RCT · 4 weeks
Dose studied, every finding
8 g/day dried watercress powder in 500 mg capsules for 28 days (estimated 195 mg total glucosinolates/day)
Population, every finding
Thai adults aged 40-59 years with low-to-moderate cardiovascular risk (predicted 10-year Framingham CVD risk <15%) and at least one cardiometabolic risk factor, taking no documented medications

No finding here moved its endpoint.

Study record

Design
randomised controlled trial
Species
human
Population
Thai adults aged 40–59 years with low-to-moderate cardiovascular disease risk and at least one cardiometabolic risk factor
Participants
26
Comparator
placebo
Duration
28 days
Endpoints measured
49